These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
224 related items for PubMed ID: 10969920
1. End results in central precocious puberty with GnRH analog treatment: the data of the Italian Study Group for Physiopathology of Puberty. Antoniazzi F, Arrigo T, Cisternino M, Galluzzi F, Bertelloni S, Pasquino AM, Borrelli P, Osio D, Mengarda F, De Luca F, Tatò L. J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():773-80. PubMed ID: 10969920 [Abstract] [Full Text] [Related]
2. Combined therapy with GnRH analog plus growth hormone in central precocious puberty. Pucarelli I, Segni M, Ortore M, Moretti A, Iannaccone R, Pasquino AM. J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():811-20. PubMed ID: 10969926 [Abstract] [Full Text] [Related]
3. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females. Bertelloni S, Baroncelli GI, Sorrentino MC, Perri G, Saggese G. Eur J Pediatr; 1998 May; 157(5):363-7. PubMed ID: 9625331 [Abstract] [Full Text] [Related]
4. Factors influencing final/near-final height in 12 boys with central precocious puberty treated with gonadotrophin-releasing hormone agonists. Italian Study Group of Physiopathology of Puberty. Rizzo V, De Sanctis V, Corrias A, Fortini M, Galluzzi F, Bertelloni S, Guarneri MP, Pozzan G, Cisternino M, Pasquino AM. J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():781-6. PubMed ID: 10969921 [Abstract] [Full Text] [Related]
5. [Comparison between complete and incomplete suppression of the hypophyseal-gonadal axis in girls with central precocious puberty: effect on growth and prospective final height]. Partsch CJ, Hümmelink R, Sippell WG, Oostdijk W, Odink RJ, Drop SL. Monatsschr Kinderheilkd; 1993 Dec; 141(12):935-9. PubMed ID: 8114776 [Abstract] [Full Text] [Related]
6. Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty: influence on growth and predicted final height. The German-Dutch Precocious Puberty Study Group. Partsch CJ, Hümmelink R, Peter M, Sippell WG, Oostdijk W, Odink RJ, Drop SL. Horm Res; 1993 Dec; 39(3-4):111-7. PubMed ID: 8262471 [Abstract] [Full Text] [Related]
11. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, Di Nardo R. J Clin Endocrinol Metab; 2008 Jan; 93(1):190-5. PubMed ID: 17940112 [Abstract] [Full Text] [Related]
13. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs. Lanes R, Soros A, Jakubowicz S. J Pediatr Endocrinol Metab; 2004 May; 17(5):759-66. PubMed ID: 15237711 [Abstract] [Full Text] [Related]
14. Variations in pituitary-gonadal suppression during intranasal buserelin and intramuscular depot-triptorelin therapy for central precocious puberty. Belgian Study Group for Pediatric Endocrinology. Heinrichs C, Craen M, Vanderschueren-Lodeweyckx M, Malvaux P, Fawe L, Bourguignon JP. Acta Paediatr; 1994 Jun; 83(6):627-33. PubMed ID: 7919761 [Abstract] [Full Text] [Related]
15. When to stop GnRH analog therapy: the experience of the Italian Study Group for Physiopathology of Puberty. Arrigo T, Cisternino M, Galluzzi F, Bertelloni S, Pasquino AM, Antoniazzi F, Borrelli P, Crisafulli G, Wasniewska M, De Luca F. J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():759-64. PubMed ID: 10969918 [Abstract] [Full Text] [Related]
16. Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. Arrigo T, Cisternino M, Galluzzi F, Bertelloni S, Pasquino AM, Antoniazzi F, Borrelli P, Crisafulli G, Wasniewska M, De Luca F. Eur J Endocrinol; 1999 Aug; 141(2):140-4. PubMed ID: 10427157 [Abstract] [Full Text] [Related]
17. Effects of combined gonadotropin-releasing hormone agonist and growth hormone therapy on adult height in precocious puberty: a further contribution. Pucarelli I, Segni M, Ortore M, Arcadi E, Pasquino AM. J Pediatr Endocrinol Metab; 2003 Sep; 16(7):1005-10. PubMed ID: 14513877 [Abstract] [Full Text] [Related]
18. Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues. Bertelloni S, Baroncelli GI, Ferdeghini M, Menchini-Fabris F, Saggese G. Eur J Pediatr; 2000 May; 159(5):369-74. PubMed ID: 10834524 [Abstract] [Full Text] [Related]
19. Long-term results with a slow-release gonadotrophin-releasing hormone agonist in central precocious puberty. Dutch-German Precocious Puberty Study Group. Oostdijk W, Drop SL, Odink RJ, Hümmelink R, Partsch CJ, Sippell WG. Acta Paediatr Scand Suppl; 1991 May; 372():39-45; discussion 46. PubMed ID: 1833950 [Abstract] [Full Text] [Related]
20. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty. Carel JC, Roger M, Ispas S, Tondu F, Lahlou N, Blumberg J, Chaussain JL. J Clin Endocrinol Metab; 1999 Jun; 84(6):1973-8. PubMed ID: 10372696 [Abstract] [Full Text] [Related] Page: [Next] [New Search]